Epidemiological Characteristics of Drug Use and Effectiveness of Methadone Substitution Therapy in Hiv-Positive Injecting Drug Users Infected With Viral Hepatitis C in Minsk

Shylava, M.A.; Abramovich, A. V.; Valchuk, I. N.; Dotsenko, Marina; Чистенко, Г. Н.; Жаворонок, С. В.

doi:10.25298/2616-5546-2020-4-1-81-85

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During this period, the number of HIV‐positive patients among these programme participants increased up to 26.3%, and all of them were receiving anti‐HIV treatment. However, 100% were also HCV positive, but none of them was treated for viral hepatitis 22 …”

Section: Belarusmentioning

confidence: 99%

“…However, 100% were also HCV positive, but none of them was treated for viral hepatitis. 22 All known DAAs combinations, except SOF/VEL/VOX, have been approved in Belarus, but access to reimbursement is restricted, like in other EE countries. 19 However, unlike Russia, where access to the treatment is highly dependent upon the region the patient lives in, the indications for and access to treatment in Belarus are regulated by order of the Ministry of Health (June 1, 2017), which determines which groups of patients have priority for reimbursement of treatment.…”

Section: B El Arusmentioning

confidence: 99%

See 1 more Smart Citation

Is elimination of hepatitis C virus realistic by 2030: Eastern Europe

Isakov

Цыркунов

Nikityuk

2021

Liver International

View full text Add to dashboard Cite

The WHO elimination goals (diagnosis of 90% of the cases of hepatitis C virus (HCV), treatment coverage in 80% and a 65% reduction in deaths from HCV) are set to be reached by 2030. Although these elimination programmes are extremely important in the Eastern European countries (Russia, Ukraine, Belarus and Moldova) with a high prevalence of HCV, limited economic resources prevent their development and implementation. Regardless of the decrease in the incidence HCV in all Eastern European countries, low diagnosis and treatment access, especially in high‐risk populations, will not allow to achieve HCV elimination or even to control the infection by 2030.

show abstract

Section: Belarusmentioning

confidence: 99%

Section: B El Arusmentioning

confidence: 99%